Sinovac applies for conditional marketing authorization of COVID-19 vaccine
BEIJING -- Beijing-based Sinovac Life Sciences Co., Ltd. on Wednesday filed an application with Chinese authorities for conditional marketing authorization of its anti-COVID-19 vaccine CoronaVac.
The application has been received by the National Medical Products Administration (NMPA), according to Sinovac Biotech Ltd., which has a majority stake in the vaccine producer.
The inactivated vaccine CoronaVac has made progress in phase three clinical trials overseas, showing a good level of safety after inoculation, according to a company statement.
Fourteen days after the inoculation of two doses of CoronaVac, the effectiveness of the vaccine in protecting against diseases caused by COVID-19 has met the relevant technical standards laid out by the World Health Organization and the requirements of the NMPA, the statement said.
- China ramping up Nipah virus surveillance
- Shanghai to host embodied intelligence expo in July
- Chongqing sets GDP growth target of over 5% for 2026
- Xinjiang strengthens economic, cultural ties with Hong Kong, Macao
- Former senior political adviser sentenced to 12 years for bribery
- Hubei's government becomes first in China to add 'emotional value' to work report
